Clinical trials: Epithelial Tumor, Malignant
Renal Cancer Cell
Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
The study aims to evaluate the efficacy of a third TKI after two previous lines of therapy with TKIs, in terms of median progression free survival (mPFS), in patients affected by metastatic renal cancer cell.
- Trial name
- TOKIO (NCT03456401)
- Testing
- Sorafenib or Sunitinib
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cholangiocarcinoma, Intrahepatic
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative…
- Trial name
- NCT04506281
- Testing
- neoadjuvant treatment
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-small Cell Lung Cancer, Stereotactic Body Radiotherapy
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Older patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) often die from other causes than lung cancer due to age-related comorbidities.
- Conditions
- Non-small Cell Lung Cancer, Stereotactic Body Radiotherapy, Comprehensive Geriatric Assessment
- Trial name
- LIVELUNG (NCT05919641)
- Testing
- Comprehensive Geriatric Assessment
- Where
- 4 sites in Denmark
- Volunteers
- 130 people
- Sponsor
- Odense University Hospital
Kidney Tumor
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy
The primary objective is to determine if 3D modelling shortens total console operation time as a surrogate endpoint for clinical outcomes like perioperative complications and morbidity in robotic-assisted partial nephrectomy.
- Trial name
- 3DPN (NCT06056505)
- Testing
- partial kidney nephrectomy, DaVinci Robot, Innersight 3D software
- Where
- 10 sites in Germany
- Volunteers
- 370 people
- Sponsor
- University of Leipzig
Recurrent Non-small Cell Lung Cancer
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format…
- Trial name
- CCODG-NSCLC (NCT02889666)
- Testing
- Cisplatin, Carboplatin, Docetaxel
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Carcinoma, Non-Small-Cell Lung
A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
This is an open-label multicenter, phase 1-2 study. Following determination of the recommended AEG35156 dose in combination with carboplatin and paclitaxel in the initial Phase 1 part of this study, additional patients will be…
- Trial name
- NCT00558922
- Testing
- AEG35156
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Aegera Therapeutics
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT06003231
- Testing
- disitamab vedotin
- Where
- 96 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Head and Neck Cancer
Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, S-1, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625937
- Testing
- cisplatin, docetaxel, tegafur-gimeracil-oteracil potassium
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Yonsei University
Head and Neck Squamous Cell Carcinoma
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
- Trial name
- TRACE (NCT00174837)
- Testing
- Tirapazamine, Cisplatin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Carcinoma, Renal Cell
An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
Purpose: The purpose of the correlative studies is to evaluate levels of serum factors of circulating VEGF and soluble VEGFR, circulating tumor cells and circulating endothelial cells assayed at baseline and over the course of…
- Trial name
- NCT00538772
- Testing
- Not applicable - blood tests/tissue specimen tests will be undertaken
- Where
- 3 sites in Canada
- Sponsor
- Kim Chi
Non-small Cell Lung Cancer, Radiation Toxicity
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent…
- Trial name
- RICT-LUNG (NCT03416972)
- Testing
- Standard platinum-based chemoradiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Colorectal Carcinoma, Cancer
Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies
This original research investigates the critical issue of gastrointestinal (GI) second primary malignancies (SPMs) in patients with signet ring cell carcinoma (SRCC), a rare and aggressive subtype of colorectal cancer.
- Conditions
- Colorectal Carcinoma, Cancer, Signet Ring Adenocarcinoma of the Colon
- Trial name
- NCT06978595
- Where
- Egypt
- Volunteers
- 8,171 people
- Sponsor
- asmaa salama ibrahim
Head and Neck Squamous Cell Carcinoma
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
This study evaluates the efficacy of the new docetaxel-cisplatin-cetuximab regimen (TPEx) versus the standard platinum-5FU-cetuximab EXTREME regimen as a first-line treatment in recurrent and/or metastatic HNSCC.
- Trial name
- TPExtreme (NCT02268695)
- Testing
- Cisplatin, 5-Fluorouracile, Docetaxel
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 541 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Hepatocellular Carcinoma
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
- Trial name
- CLeAR (NCT07365839)
- Testing
- Arm 1 cemiplimab, Arm 2 cemiplimab and fianlimab
- Sponsor
- Virginia Commonwealth University
Advanced Liver Cancer
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT05603039
- Testing
- QL1706, QL1604, Bevacizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Carcinoma
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy.
- Trial name
- NCT05557877
- Testing
- Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Malignant Mesothelioma
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of bortezomib and how well it works in treating patients…
- Trial name
- NCT00513877
- Testing
- bortezomib, quality-of-life assessment
- Where
- 13 sites in Belgium, Ireland and 2 more
- Volunteers
- 33 people
- Sponsor
- Cancer Trials Ireland
Resectable Lung Non-Small Cell Carcinoma
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage…
- Trial name
- NCT06775275
- Testing
- Adebellizumab, Bevacizumab, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Carcinoma, Ductal, Breast
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
The Neo-PREDICT-HER2 Study is phase II trial to validate predictive markers for the response evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast cancer.
- Trial name
- NCT01891357
- Testing
- Biopsy before and after three weeks of study treatment, paclitaxel, lapatinib
- Where
- 10 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Women's Cancer Study Group GmbH
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.